Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can effectively shrink or eliminate tumors in ...

A short course of immunotherapy given before surgery eliminated detectable colon cancer in a majority of patients whose ...

People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

Hundreds of women with aggressive cervical cancer are to be offered a new immunotherapy on the NHS, which could help more women survive and ...

An international team led by a UK investigator finds that the immunotherapy drug pembrolizumab when given with chemotherapy for early-stage triple-negative breast cancer (TNBC) in the randomised ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Lyndsey Ambler, from the charity, said: "Adding immunotherapy to standard cancer treatment could improve people's chances of ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...